The Colton Center for Autoimmunity at Yale has announced $750,000 in awards to seven faculty-led research projects targeting autoimmune and allergic diseases — conditions that affect an estimated 23.5 million Americans. The funded projects span a range of diseases including celiac disease, Type 1 diabetes, psoriasis, and hidradenitis suppurativa, with each team bringing a novel scientific approach to diagnosis, prevention, or treatment.
Beyond funding, the awards come with expert mentorship and business training designed to help researchers navigate the path to commercialization — a critical gap the Colton Center was specifically founded to address. Many promising scientific discoveries stall without the proof-of-concept and validation studies needed to attract commercial partners or launch a startup. These grants are designed to carry research over exactly that hurdle.
This year’s awardees include faculty from Yale’s departments of Immunobiology, Dermatology, Chemistry, and Pathology, reflecting the center’s commitment to cross-disciplinary collaboration. Notable projects include the development of insulin-producing beta cells resistant to autoimmune destruction, a noninvasive skin protein assessment tool for inflammatory skin disease treatment, and a new humanized mouse model serving as a surrogate for human celiac disease.
Established in 2019 through a gift from philanthropists Judith and Stewart Colton, the center operates under the scientific direction of Dr. Joseph Craft and is housed within Yale Ventures. Applications for the 2024 funding cycle open September 5, 2023.
Featured Experts

Sara Baier, MEd
Associate Director of External Relations, Colton Consortium for Autoimmunity
Colton Center for Autoimmunity, Perelman School of Medicine, University of Pennsylvania
Jennifer Gillen, MBA
Administrative Manager, Judith & Stewart Colton Center for Autoimmunity (NYU)
Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health, New York University
Kenneth Hassinger
Director of Finance, Colton Consortium for Autoimmunity
Colton Center for Autoimmunity, Perelman School of Medicine, University of PennsylvaniaFeatured Projects

The Role and Mechanism of Aberrant Dendritic Cell Function in Autoimmunity
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.

Utilizing RNA Replicons as Immune Modulators for Systemic Lupus Erythematosus
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Featured Publications
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
Transcription factor Etv3 controls the tolerogenic function of dendritic cells
Related News

A Growing Network Takes Stock: Highlights from the 2026 Colton Consortium Symposium
Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.

$5M Gift Establishes Colton Center for Autoimmunity at Mount Sinai to Advance Precision Medicine for Autoimmune Diseases
A $5 million gift from Judith and Stewart Colton establishes a Colton Center for Autoimmunity at Mount Sinai, expanding the Colton Consortium and advancing precision, early-detection approaches to autoimmune disease research.

What a "Silenced" Chromosome Can Tell Us About Autoimmunity
Penn Colton Center researcher Montserrat Anguera reveals how B cells maintain X chromosome inactivation, and how its breakdown drives lupus, offering new insight into female-biased autoimmune disease and treatment targets.